VMD spotlights managed access for canine mast cell cancer care

CURRENT FULL VERSION: VMD Sciences is using a single canine oncology case to make a broader point about access. The company announced January 30, 2026 that it supported Dr. Seth Glasser, DVM, DipACVIM (Oncology), at Garden State Veterinary Specialists in importing a Europe-approved tyrosine kinase inhibitor for Jetta, an 8-year-old mixed-breed dog with metastatic mast cell cancer, after standard treatment options had failed. According to the company, the drug is approved by the European Medicines Agency but not available in the U.S., and the import was completed through VMD’s managed access program. (static1.squarespace.com)

The backdrop is a veterinary oncology market where treatment innovation is moving faster than regulatory harmonization. In canine mast cell tumors, U.S. clinicians already have several established or emerging options, including surgery, radiation, chemotherapy, FDA-approved toceranib phosphate for certain recurrent cutaneous mast cell tumors, and more recent immunotherapy options such as gilvetmab for specialists practicing oncology. The diagnostic side is moving too. IDEXX said in January 2026 that it plans to expand its Cancer Dx Panel to include canine mast cell tumor detection starting in mid-2026, without changing sample requirements or the usual two- to three-day turnaround time, and to add mast cell tumor FNA cytology to its inVue Dx Cellular Analyzer for in-clinic assessment during the patient visit. That matters because mast cell tumors are common, can resemble benign skin masses, and still lack a single test that reliably detects disease throughout the body before it becomes clinically apparent. (fda.gov)

VMD said Jetta had a low-grade subcutaneous mast cell tumor with lymph node metastasis. Dr. Glasser, whose practice biography notes a focus on multimodal cancer care and quality of life, identified the imported targeted inhibitor as the next best option and submitted medical records, a prescription, and clinical justification. VMD said it then handled regulatory support through customs clearance and secondary FDA inspection. In the release, Glasser said the process required about 10 minutes of his time and that the product arrived in days, while founder Jeff Oliva framed the case as evidence that managed access programs remain underused in veterinary medicine. (static1.squarespace.com)

The company didn't name the product in the release, but the description strongly suggests a European veterinary oncology TKI used in canine mast cell disease. One likely candidate is masitinib, marketed in Europe as Masivet and authorized by the EMA for dogs with non-resectable mast cell tumors with confirmed c-Kit mutation. Because VMD did not identify the drug, that remains an inference rather than a confirmed fact. Still, the clinical logic is consistent with the broader literature: TKIs remain a key option for inoperable or metastatic mast cell tumors, and a 2025 retrospective study of imatinib in 35 dogs with mast cell tumors reported clinical benefit in 77% of cases, with generally manageable toxicity. (ema.europa.eu)

Industry reaction in this case is mostly coming from the access side rather than outside commentators. VMD is positioning managed access as a service layer for veterinarians seeking treatments not currently available in their region, and separately describes managed entry programs as a way to broaden adoption of approved therapies through sponsor-supported frameworks. That suggests the company sees these cases not only as patient-specific rescues, but also as market-building exercises that could help manufacturers gauge demand and clinical uptake before wider launches. (vmdsciences.com)

Why it matters: For veterinary professionals, the significance isn't just the imported drug. It's the precedent. In referral oncology, especially for mast cell tumors with metastasis or relapse, clinicians are increasingly expected to think across surgery, radiation, systemic therapy, immunotherapy, supportive care, and molecularly targeted options. Supportive care is not a side issue here. The FDA recently renewed conditional approval of Jaguar Health’s Canalevia-CA1, a delayed-release crofelemer tablet for chemotherapy-induced diarrhea in dogs, through December 21, 2026. The drug targets chloride ion secretion in the gut rather than simply slowing motility, and its continued availability gives oncologists one more indication-specific tool to help maintain hydration, comfort, nutrition, and treatment adherence in dogs receiving chemotherapy while Jaguar works toward full approval. A managed access pathway creates one more lever when domestic formularies fall short, provided the case is well documented and the regulatory process is handled correctly. That could be especially relevant as more veterinary cancer therapeutics reach regional markets unevenly, leaving U.S. specialists aware of tools they can't routinely prescribe. (static1.squarespace.com)

There are also practical limits. Managed access is case-based, compliance-heavy, and unlikely to replace standard approvals or labeled use. It may be best suited to specialty settings where oncologists can justify need, monitor adverse events closely, and counsel pet parents about uncertainty, cost, and logistics. For general practitioners, the takeaway may be less about importing drugs directly and more about knowing when referral centers may have additional avenues for refractory mast cell disease. At the same time, earlier detection tools may change who gets referred and when: IDEXX says more than 5,500 clinics already use its Cancer Dx Panel, mainly for lymphoma screening, and its planned mast cell tumor expansion and slide-free in-clinic cytology workflow are aimed at faster assessment of suspicious skin masses and quicker treatment decisions. (static1.squarespace.com)

What to watch: The next signal will be whether VMD or drug sponsors disclose more case volume, name the imported oncology agents involved, or use managed access demand to support broader managed entry programs or eventual U.S. regulatory filings. It will also be worth watching whether better front-end mast cell tumor detection and stronger supportive-care options translate into earlier intervention, smoother chemotherapy courses, and a larger practical role for specialty oncology pathways. (vmdsciences.com)